JP2024502258A - Ｃｇａｓに関連する状態の処置に有用なインドール誘導体 - Google Patents
Ｃｇａｓに関連する状態の処置に有用なインドール誘導体 Download PDFInfo
- Publication number
- JP2024502258A JP2024502258A JP2023537694A JP2023537694A JP2024502258A JP 2024502258 A JP2024502258 A JP 2024502258A JP 2023537694 A JP2023537694 A JP 2023537694A JP 2023537694 A JP2023537694 A JP 2023537694A JP 2024502258 A JP2024502258 A JP 2024502258A
- Authority
- JP
- Japan
- Prior art keywords
- triazol
- methoxy
- chloro
- methyl
- fluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063128949P | 2020-12-22 | 2020-12-22 | |
| US63/128,949 | 2020-12-22 | ||
| PCT/IB2021/062029 WO2022137085A1 (en) | 2020-12-22 | 2021-12-20 | Indole derivatives useful in treating conditions associated with cgas |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024502258A true JP2024502258A (ja) | 2024-01-18 |
| JP2024502258A5 JP2024502258A5 (https=) | 2025-01-06 |
Family
ID=79164465
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023537694A Pending JP2024502258A (ja) | 2020-12-22 | 2021-12-20 | Ｃｇａｓに関連する状態の処置に有用なインドール誘導体 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US12404261B2 (https=) |
| EP (1) | EP4267564A1 (https=) |
| JP (1) | JP2024502258A (https=) |
| KR (1) | KR20230124665A (https=) |
| CN (1) | CN116635382A (https=) |
| AR (1) | AR124443A1 (https=) |
| AU (1) | AU2021404953A1 (https=) |
| CA (1) | CA3202212A1 (https=) |
| CL (1) | CL2023001859A1 (https=) |
| CO (1) | CO2023007954A2 (https=) |
| CR (1) | CR20230282A (https=) |
| DO (1) | DOP2023000129A (https=) |
| EC (1) | ECSP23045506A (https=) |
| IL (1) | IL303913A (https=) |
| JO (1) | JOP20230146A1 (https=) |
| MX (1) | MX2023007467A (https=) |
| PE (1) | PE20240229A1 (https=) |
| PY (1) | PY21111338A (https=) |
| SA (1) | SA523441335B1 (https=) |
| TW (1) | TW202241873A (https=) |
| UY (1) | UY39579A (https=) |
| WO (1) | WO2022137085A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023179378A (ja) * | 2022-06-02 | 2023-12-19 | イーライ リリー アンド カンパニー | ｃＧＡＳ阻害剤 |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202132316A (zh) | 2019-11-04 | 2021-09-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| CA3194067A1 (en) | 2020-09-15 | 2022-03-24 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202430156A (zh) | 2022-10-18 | 2024-08-01 | 英商葛蘭素史密斯克藍智慧財產發展有限公司 | 化合物 |
| KR20250131845A (ko) * | 2022-12-20 | 2025-09-03 | 벤투스 테라퓨틱스 유에스 인코포레이티드 | 고리형 gmp-amp 생성효소 억제제로서 싸이아다이아졸 유도체 및 이의 용도 |
| AU2023409125A1 (en) | 2022-12-21 | 2025-06-26 | Eli Lilly And Company | Azepino[4,5-b]indolone cgas inhibitors |
| TW202440093A (zh) * | 2023-03-06 | 2024-10-16 | 香港商英矽智能科技知識產權有限公司 | Cdk8/19雙重抑制劑及其使用方法 |
| WO2025215082A1 (en) * | 2024-04-11 | 2025-10-16 | Glaxosmithkline Intellectual Property Development Limited | Fused azines for the treatment of inflammatory diseases |
| WO2025231011A1 (en) * | 2024-05-01 | 2025-11-06 | Omniab, Inc. | Heteroarylindole inhibitors of apol-1 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010522723A (ja) * | 2007-03-29 | 2010-07-08 | ノバルティス アーゲー | 増殖性疾患の処置のための３−イミダゾリル−インドール |
| JP2016506408A (ja) * | 2012-12-19 | 2016-03-03 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | 哺乳動物の環状ジヌクレオチドシグナル伝達経路の薬学的標的化 |
| JP2016524593A (ja) * | 2013-04-29 | 2016-08-18 | メモリアル スローン−ケタリング キャンサー センター | セカンドメッセンジャーのシグナル伝達を変えるための組成物及び方法 |
| WO2019153002A1 (en) * | 2018-02-05 | 2019-08-08 | Lama Lodoe | 2,3,4,5-tetrahydro-1h-pyrido[4, 3-b]indole inhibitors of cgas for treating autoinflammatory diseases |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20040874A1 (it) * | 2004-04-30 | 2004-07-30 | Ist Naz Stud Cura Dei Tumori | Derivati indolici ed azaindolici con azione antitumorale |
| MX2010014394A (es) | 2008-06-20 | 2011-05-19 | Rottapharm Spa | Derivados de 6-1h-imidazo-quinazolina y quinolinas, nuevos inhibidores de monoamina oxidasa y ligandos del receptor de imidazolina. |
| US9096579B2 (en) | 2012-04-20 | 2015-08-04 | Boehringer Ingelheim International Gmbh | Amino-indolyl-substituted imidazolyl-pyrimidines and their use as medicaments |
| WO2016103037A1 (en) | 2014-12-22 | 2016-06-30 | Akarna Therapeutics, Ltd. | Fused bicyclic compounds for the treatment of disease |
| WO2018140513A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer |
| SG11202002218VA (en) | 2017-09-15 | 2020-04-29 | Aduro Biotech Inc | Pyrazolopyrimidinone compounds and uses thereof |
| MX2020008265A (es) * | 2018-02-16 | 2020-09-21 | UCB Biopharma SRL | Derivados farmaceuticos del anillo heterobiciclico 6,5. |
| WO2020123422A1 (en) | 2018-12-10 | 2020-06-18 | Aduro Biotech, Inc. | Imidazopyridazinone compounds and uses thereof |
| CA3125626A1 (en) | 2019-01-04 | 2020-07-09 | Bellbrook Labs, Llc | Inhibitors of cgas activity as therapeutic agents |
| US12522603B2 (en) | 2019-03-13 | 2026-01-13 | The Rockefeller University | Inhibitors of gas for treating autoinflammatory diseases and cancer metastasis |
| WO2021209475A1 (en) | 2020-04-16 | 2021-10-21 | F. Hoffmann-La Roche Ag | Sulfamoylamide derivatives |
| US20230192623A1 (en) | 2020-04-16 | 2023-06-22 | Hoffmann-La Roche Inc. | Indazole Derivatives |
| JP2023522327A (ja) | 2020-04-16 | 2023-05-30 | エフ． ホフマン－ラ ロシュ アーゲー | ベンズイミダゾール誘導体 |
| WO2021209473A1 (en) | 2020-04-16 | 2021-10-21 | F. Hoffmann-La Roche Ag | Biphenyl derivatives |
| US20230348398A1 (en) | 2020-04-16 | 2023-11-02 | Hoffmann-La Roche Inc. | Benzimidazole derivatives |
| KR20230062845A (ko) | 2020-09-03 | 2023-05-09 | 이뮨센서 테라퓨틱스, 인코포레이티드 | 퀴놀린 cgas 길항제 화합물 |
| AU2021349249A1 (en) | 2020-09-24 | 2023-04-13 | Ventus Therapeutics U.S., Inc. | Pyrido(4,3-b)indole derivatives and their use as pharmaceuticals |
-
2021
- 2021-12-20 WO PCT/IB2021/062029 patent/WO2022137085A1/en not_active Ceased
- 2021-12-20 CR CR20230282A patent/CR20230282A/es unknown
- 2021-12-20 JP JP2023537694A patent/JP2024502258A/ja active Pending
- 2021-12-20 AU AU2021404953A patent/AU2021404953A1/en active Pending
- 2021-12-20 US US17/645,071 patent/US12404261B2/en active Active
- 2021-12-20 UY UY0001039579A patent/UY39579A/es unknown
- 2021-12-20 PY PY202121111338A patent/PY21111338A/es unknown
- 2021-12-20 KR KR1020237024854A patent/KR20230124665A/ko active Pending
- 2021-12-20 AR ARP210103590A patent/AR124443A1/es unknown
- 2021-12-20 CA CA3202212A patent/CA3202212A1/en active Pending
- 2021-12-20 PE PE2023001937A patent/PE20240229A1/es unknown
- 2021-12-20 EP EP21834940.5A patent/EP4267564A1/en active Pending
- 2021-12-20 TW TW110147655A patent/TW202241873A/zh unknown
- 2021-12-20 IL IL303913A patent/IL303913A/en unknown
- 2021-12-20 MX MX2023007467A patent/MX2023007467A/es unknown
- 2021-12-20 CN CN202180079723.3A patent/CN116635382A/zh active Pending
-
2023
- 2023-06-20 JO JOJO/P/2023/0146A patent/JOP20230146A1/ar unknown
- 2023-06-20 CO CONC2023/0007954A patent/CO2023007954A2/es unknown
- 2023-06-20 CL CL2023001859A patent/CL2023001859A1/es unknown
- 2023-06-20 EC ECSENADI202345506A patent/ECSP23045506A/es unknown
- 2023-06-21 DO DO2023000129A patent/DOP2023000129A/es unknown
- 2023-06-21 SA SA523441335A patent/SA523441335B1/ar unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010522723A (ja) * | 2007-03-29 | 2010-07-08 | ノバルティス アーゲー | 増殖性疾患の処置のための３−イミダゾリル−インドール |
| JP2016506408A (ja) * | 2012-12-19 | 2016-03-03 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | 哺乳動物の環状ジヌクレオチドシグナル伝達経路の薬学的標的化 |
| JP2016524593A (ja) * | 2013-04-29 | 2016-08-18 | メモリアル スローン−ケタリング キャンサー センター | セカンドメッセンジャーのシグナル伝達を変えるための組成物及び方法 |
| WO2019153002A1 (en) * | 2018-02-05 | 2019-08-08 | Lama Lodoe | 2,3,4,5-tetrahydro-1h-pyrido[4, 3-b]indole inhibitors of cgas for treating autoinflammatory diseases |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023179378A (ja) * | 2022-06-02 | 2023-12-19 | イーライ リリー アンド カンパニー | ｃＧＡＳ阻害剤 |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023007467A (es) | 2023-07-04 |
| KR20230124665A (ko) | 2023-08-25 |
| EP4267564A1 (en) | 2023-11-01 |
| DOP2023000129A (es) | 2023-07-16 |
| CA3202212A1 (en) | 2022-06-30 |
| AU2021404953A9 (en) | 2024-02-08 |
| AU2021404953A1 (en) | 2023-06-22 |
| TW202241873A (zh) | 2022-11-01 |
| WO2022137085A1 (en) | 2022-06-30 |
| CR20230282A (es) | 2023-07-12 |
| AR124443A1 (es) | 2023-03-29 |
| CL2023001859A1 (es) | 2024-02-09 |
| SA523441335B1 (ar) | 2025-04-20 |
| CN116635382A (zh) | 2023-08-22 |
| IL303913A (en) | 2023-08-01 |
| US20230085472A1 (en) | 2023-03-16 |
| ECSP23045506A (es) | 2023-07-31 |
| PY21111338A (es) | 2022-07-18 |
| UY39579A (es) | 2022-07-29 |
| PE20240229A1 (es) | 2024-02-16 |
| US12404261B2 (en) | 2025-09-02 |
| JOP20230146A1 (ar) | 2023-06-20 |
| CO2023007954A2 (es) | 2023-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7487421B2 (ja) | Ｐｒｍｔ５阻害剤 | |
| JP2024502258A (ja) | Ｃｇａｓに関連する状態の処置に有用なインドール誘導体 | |
| JP7041198B2 (ja) | Ｊａｋ阻害剤である５－クロロ－２－ジフルオロメトキシフェニルピラゾロピリミジン化合物 | |
| US9187464B2 (en) | TRPV4 antagonists | |
| AU2019226480A1 (en) | Pharmaceutical compounds | |
| JP6564406B2 (ja) | カゼインキナーゼ１デルタ／イプシロン阻害剤としてのイミダゾ−ピリダジン誘導体 | |
| JP6900491B2 (ja) | ピラゾロピリミジン化合物及びその使用方法 | |
| TW201247673A (en) | Imidazo[5,1-f][1,2,4]triazines for the treatment of neurological disorders | |
| JP2018521025A (ja) | Ｔｎｆ活性のモジュレーターとしてのベンゾオキサジノン誘導体およびその類似体 | |
| KR20160086930A (ko) | 피롤로피롤론 유도체 및 bet 억제제로서의 그의 용도 | |
| JP6283688B2 (ja) | カゼインキナーゼ１ｄ／ｅ阻害剤としての新規なピラゾール置換のイミダゾピラジン | |
| JP2024500841A (ja) | ｃＧＡＳと関連する病態の処置に有用なピロロ［３．２－ｂ］ピリジン誘導体 | |
| US11814384B2 (en) | Inhibtors of Raf kinases | |
| TWI829481B (zh) | 雙環吲唑糖皮質素受體拮抗劑 | |
| EP3986900A1 (en) | Tetrazole-substituted pyrazolopyrimidine inhibitors of jak kinases and uses thereof | |
| AU2017324281A1 (en) | 8-(azetidin-1-yl)-[1,2,4]triazolo[1,5-A]pyridinyl compounds, compositions and methods of use thereof | |
| JP2024528073A (ja) | 有機ピリジン－ピラゾール化合物及びその使用 | |
| EP3265464A1 (en) | Triazolopyridine compounds and methods of use thereof | |
| WO2025160079A1 (en) | Indazolo-amino-pyrimidinone compounds | |
| HK1245783A1 (en) | Triazolopyridine compounds and methods of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241220 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20241220 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20251030 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20251118 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20251205 |